Copper Histidinate Treatment for Menkes Disease

Menkes Disease Clinical Trial

Official title:
Copper Histidinate Treatment for Menkes Disease

Status Available

Clinical Trial Summary

This study investigates the clinical effects and safety of subcutaneous Copper Histidinate treatment for newly diagnosed Menkes disease patients under 6 years of age.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Menkes Disease

Clinical Trial Details

NCT number	NCT04074512
Study type	Expanded Access
Source	Sentynl Therapeutics, Inc.
Contact	Sentynl Therapeutics Study Team
Phone	888-507-5206
Email	studyinfo@sentynl.com
Status	Available
Phase

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05687474` - Baby Detect : Genomic Newborn Screening
Enrolling by invitation	`NCT03655223` - Early Check: Expanded Screening in Newborns
Recruiting	`NCT04977388` - NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Occipital Horn Syndrome	Phase 1/Phase 2
Completed	`NCT00811785` - Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency	Phase 3
Enrolling by invitation	`NCT04337684` - Long Term Follow-up on Menkes Disease Patients